BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

GC Genome Discovers Gut Microbiome Link to High Blood Pressure in New Study

GC Genome Corporation, a leading genomic diagnostics company, announced the publication of a study in Frontiers in Microbiomes. This study demonstrate...

June 15, 2023 | News

Helfgott Institute Gets Funding to Test Mind-Body Practices for Benzodiazepine Reduction

This one-time opportunity is made possible by the US Deprescribing Network, funded by the National Institute on Aging, in support of complementary and...

April 10, 2023 | News

Phase 1 trial of OLX72021of Treatment of Androgenic Alopecia has been approved for initiation in Australia

OliX will evaluate the safety and tolerability of OLX72021 in Phase 1 clinical trial Excellent hair growth effect is observed when used as external solu...

March 27, 2023 | News

ThoughtFull raises US$4M in Pre-Series A round led by Temasek-owned Sheares Healthcare Group

ThoughtFull, Asia's first digital mental health company that provides seamless end-to-end mental healthcare for all, announced today that it has ...

March 23, 2023 | News

AXA Mind Health Study reveals more than half of Gen Z in Asia are suffering from poor mental health

While the COVID-19 pandemic has taken a heavy toll on mind health across society, the latest findings from the annual AXA Study of Mind Health and Wel...

March 20, 2023 | News

Hopper Health Launches Personalized Primary Care For Neurodivergent Adults

One in five adults experiences neurodivergent conditions like Autism, ADHD, Tourette's, and OCD, and is more likely to avoid care due to previous negativ...

March 17, 2023 | News

Halucenex Life Sciences Inc. targets Australian market following landmark TGA decision

Creso Pharma Limited (ASX:CPH, FRA:1X8) ('Creso Pharma') is pleased to announce its wholly-owned psychedelics subsidiary, Halucenex Life Sciences...

February 09, 2023 | News

BeiGene Aim to Accelerate Integration of Mental Health into Quality Cancer Care

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, has released a report highlighting the challenges cancer patients and car...

February 03, 2023 | News

FDA agrees to Actinogen six-month Phase 2b Alzheimer's Disease trial

Actinogen Medical Limited (ASX: ACW) is pleased to announce receipt today of agreement from the US Food and Drug Administration (FDA) to proceed with ...

December 23, 2022 | News

STADA partners with BIAL to bring Ongentys to Parkinson’s patients in Australia

STADA receives from BIAL exclusive rights to market and distribute Ongentys (opicapone) capsules in Australia STADA Specialty Head Bryan Kim: "Ongentys ...

December 19, 2022 | News

DAILY rates from anxiety disorders by age, World, 1990 to 2019

...

December 15, 2022 | Analysis

Mental Health

For 2017 this study estimates that 792 million people lived with a mental health disorder. This is slightly more than one in ten people globally (10.7%...

December 15, 2022 | Analysis | By by Saloni Dattani, Hannah Ritchie and Max Roser This article was first published in April 2018. Last updated in August 2021.

Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial

Actinogen Medical Limited (ASX: ACW) is pleased to announce that the first patient has been randomized and treated in the XanaCIDD Phase 2 depression ...

December 15, 2022 | News

Neeuro and Institute of Mental Health Launch Home-Based Attention Training Programme

Cogo is a patented and scientifically validated digital therapeutic programme that aims to equip parents with an evidence-backed tool that is efficacious i...

December 06, 2022 | News

Stay Connected